VCs name their bioinformatic hot buttons
21 March, 2002 by Malorye BrancaVenture capitalists are hungry for systems biology, data mining, and anything that targets "where the rat is in the snake," said James Sherblom, chairman and managing partner of Seaflower Ventures Inc, speaking at the biotech financing round table held on March 14 at the BioITWorld Conference and Expo in Boston.
Interview: Life science 'the next big thing, says IBM's Kovac
21 March, 2002 by Staff WritersIDG spoke with Dr Caroline Kovac, general manager of IBM Life Sciences Solutions, about her company's involvement in the life sciences.
Bridging the communications gap between bucks and biology
20 March, 2002 by Staff WritersFor an industry that's touted as the way forward for Australia's economy, there can be a surprising lack of clarity or consistency of views about the biotech sector's prognosis.
Queensland institutes in the hiring line
20 March, 2002 by Pete YoungQueensland's biotech employment outlook is bright courtesy of a State government committed to pumping hundreds of millions of dollars into bioindustry over 10 years.
No headlong rush, but biotechs still aiming for market
20 March, 2002 by Tanya HollisBiotech newcomers have been a rare event on the Australian bourse in the past six months.
New Fed science committee
20 March, 2002 by Iain ScottA new standing committe on science and technology has been announced by the Federal government.
Vic biomeds dominate BIF round funding
20 March, 2002 by Pete YoungBiomedicine companies emerged the big winners among 22 biotech hopefuls who will share $4.74 million in the latest round of Biotechnology Innovation Fund grants.
Iatia IPO closes early after big demand
20 March, 2002 by Tanya HollisOptical technologies group Iatia has closed its initial public offering two days early after successfully raising $5 million to assist its commercialisation program.
Opinion: Necessary liaisons
19 March, 2002 by Debra GoldfarbOne of the extraordinary aspects of the Bio-IT market is the notion of "scale": the scale of scientific discovery, and the possibilities derived from discovery; the scale of growth, which requires looking at multiple dimensions such as the number of biotech companies, VC investments, IT infrastructure build-out, etcetera; and the scale of complexity, by which I mean the elaborate organisational ecosystems emerging in this market.
Sydney investor grabs a $3m stake in Melbourne
18 March, 2002 by Tanya HollisA Sydney investment fund has moved to grab a stake in Melbourne bioscience commercialisation group Biocomm Services, cementing its exposure to emerging Victorian biotechnology firms.
Vic ethics committee will examine biotech
15 March, 2002 by Tanya HollisA voluntary code of ethics for the Victorian biotechnology industry was likely to be the first task of the State Government's new ethics advisory committee.
Baker and Amersham establish proteomics system
15 March, 2002 by Iain ScottA fully-automated proteomics system has been installed at Melbourne's Baker Medical Research Institute.
Axon R&D push eats up profits
13 March, 2002 by Tanya HollisAn accelerated research program helped Aussie export Axon Instruments (ASX:AXN) drive sales up 25 per cent last year, but also contributed to a significant profit slump.
Eiffel restructuring leads to modest half-year
13 March, 2002 by Tanya HollisBioengineering group Eiffel Technologies (ASX: EIF) has posted a more than three per cent fall in after-tax profits to $777,000 for the second half of last year.
Biotechs may find VC funding hard to get
11 March, 2002 by Salvatore SalamoneBioinformatics, biotech and nanotechnology companies seeking venture capital funding may have to look elsewhere, according to speakers at the Silicon Alley Breakfast Club (SABC) meeting held in New York last week (March 7).
